Korlym

Product

Last mentioned: Feb 24, 2026

Timeline

  1. Lawsuit Announced

    Rosen Law Firm announces the filing of the securities fraud class action.

  2. Appellate Loss

    Teva Pharmaceuticals wins a key appeals court decision against Corcept's Korlym patents.

  3. Class Period Ends

    Conclusion of the period following corrective disclosures or market events.

  4. Class Period Begins

    Start of the period during which alleged misleading statements were made.

Stories mentioning Korlym 1

pharma Neutral

Corcept Therapeutics Faces Securities Fraud Lawsuit Amid Korlym Patent Battle

Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.

10 sources